Clinical trials: Bullous Pemphigoid
Pemphigus, Bullous Pemphigoid
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Pemphigus is a rare autoimmune life-threatening blistering condition affecting skin and mucous membranes. Pemphigus belongs to a family of polygenic disorders.
- Conditions
- Pemphigus, Bullous Pemphigoid, Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Trial name
- NCT05284929
- Testing
- A single blood sample for HLA typing
- Where
- Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sechenov University
Bullous Pemphigoid
Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?
Bullous pemphigoid (BP) is the most common autoimmune bullous dermatosis. It mainly affects the elderly, and its cutaneous manifestations are extremely varied.
- Trial name
- NCT03636763
- Testing
- data report
- Where
- France
- Volunteers
- 183 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Uveitis, Cancer
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
This study will evaluate whether therapy that suppresses the immune system given to treat inflammatory diseases of the eye is associated with a greater risk of death and of cancer.
- Conditions
- Uveitis, Cancer, Infection, Mortality
- Trial name
- NCT00116090
- Where
- 4 sites in United States
- Volunteers
- 6,300 people
- Sponsor
- National Eye Institute (NEI)
Bullous Pemphigoid, Janus Kinase Inhibitor
JAK Inhibitors' Efficacy in Bullous Pemphigoid
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering skin disease that predominantly affects the elderly population, with rare cases reported in children and adolescents.
- Conditions
- Bullous Pemphigoid, Janus Kinase Inhibitor, Corticosteroids
- Trial name
- NCT06561256
- Testing
- Janus Kinase Inhibitor
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chao Ji
Inherited Epidermolysis Bullosa, Ichthyosis
FARD (RaDiCo Cohort) (RaDiCo-FARD)
The goal of this observational study is to conduct a prospective assessment of the individual Burden of 9 rare skin diseases to assess disability in the broadest sense of the term (psychological, social, economic and physical)…
- Conditions
- Inherited Epidermolysis Bullosa, Ichthyosis, Ectodermal Dysplasia, Incontinentia Pigmenti
- Trial name
- FARD (NCT05954416)
- Where
- 15 sites in France
- Volunteers
- 900 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Bullous Pemphigoid, Pruritus
Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission
The following is the investigators hypothesis regarding the pruritus of BP patients during remission. Anti-BP 180 IgE binds to dermal mast cells, inducing their activation and secretion of mediators after being cross-linked by…
- Trial name
- NCT01265082
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Limbal Stem Cell Deficiency, Stevens-johnson Syndrome
Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation
To investigate the effect of ocular surface reconstruction and assess the safety in cultivated oral mucosal epithelial cell sheet transplantation (COMET) regarding patients with cicatricial change of ocular surface.
- Conditions
- Limbal Stem Cell Deficiency, Stevens-johnson Syndrome, Ocular Cicatricial Pemphigoid, Chemical Burn
- Trial name
- NCT02149732
- Testing
- cultivated oral mucosal epithelial sheet transplantation
- Where
- 2 sites in South Korea
- Sponsor
- Seoul National University Hospital
Bullous Pemphigoid
Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis
Bullous pemphigoid (BP) is a chronic autoimmune subepidermal blistering disease primarily affecting the elderly with a significant risk of mortality and morbidity.
- Trial name
- BP (NCT06213909)
- Testing
- This is a retrospective analysis of health data from inpatient record, no intervention was designed
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Xijing Hospital
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals